Safety and treatment duration of ribociclib + nonsteroidal aromatase inhibitor in HR+/HER2- early breast cancer: a phase 3 randomized controlled trial (NATALEE).
- DOI
- 10.1186/s13058-026-02352-2
- Published
- 2026 Aug 4
- Container
- Breast cancer research : BCR
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s13058-026-02352-2,
title = {Safety and treatment duration of ribociclib + nonsteroidal aromatase inhibitor in HR+/HER2- early breast cancer: a phase 3 randomized controlled trial (NATALEE).},
author = {Rugo HS and Harbeck N and Hortobagyi GN and O'Shaughnessy J and Huang CS and Martin M and Juric D and Pistilli B and Xu B and De Laurentiis M and Untch M and Afenjar K and Gao M and Li Z and Bolotova N and Waters S and Barrios C},
year = {2026},
journal = {Breast cancer research : BCR},
doi = {10.1186/s13058-026-02352-2},
url = {https://doi.org/10.1186/s13058-026-02352-2}
}RIS
TY - JOUR TI - Safety and treatment duration of ribociclib + nonsteroidal aromatase inhibitor in HR+/HER2- early breast cancer: a phase 3 randomized controlled trial (NATALEE). AU - Rugo HS AU - Harbeck N AU - Hortobagyi GN AU - O'Shaughnessy J AU - Huang CS AU - Martin M AU - Juric D AU - Pistilli B AU - Xu B AU - De Laurentiis M AU - Untch M AU - Afenjar K AU - Gao M AU - Li Z AU - Bolotova N AU - Waters S AU - Barrios C PY - 2026 JO - Breast cancer research : BCR DO - 10.1186/s13058-026-02352-2 UR - https://doi.org/10.1186/s13058-026-02352-2 ER -
APA
HS, R., N, H., GN, H., J, O., CS, H., M, M., D, J., B, P., B, X., M, D. L., M, U., K, A., M, G., Z, L., N, B., S, W., & C, B. (2026). Safety and treatment duration of ribociclib + nonsteroidal aromatase inhibitor in HR+/HER2- early breast cancer: a phase 3 randomized controlled trial (NATALEE).. Breast cancer research : BCR. https://doi.org/10.1186/s13058-026-02352-2
Source records
- pubmed · retrieved 2026-11-10T13:35:55.710Z